Cancer Pain
Conditions
Keywords
Cancer pain
Brief summary
This study aims to evaluate the safety and efficacy of 3D1002 alone or in combination with oxycodone hydrochloride sustained-release tablets (OxyContin) for the management of moderate or severe cancer pain.
Detailed description
The investigational product in this study, 3D1002, is a selective antagonist of prostaglandin E2 receptor subtype 4 (EP4). The study is composed of two stages. Phase IIa stage is to assess the safety and efficacy of 3D1002 administered at doses of 50, 100 or 150 mg every 12 hour (q12h) for patients with moderate to severe cancer pain, and to determine the optimal recommended dose for further studies. Phase IIb stage is to evaluate the difference in the efficacy and safety of 3D1002 combined with OxyContin and OxyContin alone in treatment of patients with moderate to severe cancer pain.
Interventions
DRUG3D1002 (50 mg)(Phase IIa)
1 tablet of 3D1002 per oral dose
DRUG3D1002 (100 mg)(Phase IIa)
2 tablets of 3D1002 per oral dose
DRUG3D1002 (150 mg)(Phase IIa)
3 tablets of 3D1002 per oral dose
DRUG3D1002 monotherapy (Phase IIb)
3D1002 is administered at recommended dose with mimic OxyContin tablets.
DRUGOxyContin monotherapy (Phase IIb)
OxyContin is administered at an initial dose of 10 mg per dose with mimic 3D1002 tablets.
DRUG3D1002 + OxyContin (Phase IIb)
3D1002 is administered at recommended dose, and OxyContin is administered at an initial dose of 10 mg per dose.
Sponsors
3D Medicines
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Both phase IIa and IIb are randomized, parallel controlled studies.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Subject must sign the informed consent in person prior to beginning any screening procedure. 2. Age ≥18, both male and female. 3. Subjects with a malignant tumor confirmed by histopathology or cytology. 4. Weight ≥40 kg at screening period. 5. Subjects have relatively stable cancer pain and require continuous analgesic medications (estimated treatment duration ≥2 weeks), as assessed by the investigator. 6. Estimated life expectancy ≥3 months. 7. Subjects are willing to not use any analgesic other than those specified in the study during the study treatment period. 8. ECOG PS score is 0-3. 9. Have adequate organ and bone marrow function. 10. The mean NRS scores per day during the washout period are ≥4.
Exclusion criteria
1. Known allergy to any of the active ingredients or excipients of the study drug, or have a history of allergy to other opioids or non-steroidal anti-inflammatory drugs (NSAIDs) and their related ingredients. 2. Have a persistent pain resulted from other medical conditions or unknown causes. 3. Subjects presenting with emergency symptoms such as intestinal obstruction/perforation, spinal cord compression, epidural metastasis, or fracture. 4. Subjects with known active/symptomatic central nervous system metastasis and/or cancerous meningitis. 5. Subjects plan to be treated with \>10 mg/ day of prednisone or equivalent systemic corticosteroid during the study period. 6. Have a history of gastrointestinal bleeding or perforation. 7. Have a positive result of fecal occult blood test during screening period. 8. Have a history of serious cardiovascular diseases. 9. Have a history of an acute ischemic or hemorrhagic stroke within 6 months prior to screening. 10. Have a history of significant psychiatric disorders, such as schizophrenia and depression. 11. Subjects plan to receive radiotherapy, surgery, or a new regimen of systemic antitumor agents during the study treatment period (D1-D15). 12. Subjects have a history of alcohol abuse or drug abuse including opioids. 13. Subjects have significant opioid contraindications. 14. Pregnant or lactating women. 15. Subjects with other diseases that affect the oral administration or absorption of drugs. 16. Subjects are currently participating in another clinical study. 17. Other conditions deemed by the investigator to be inappropriate for participation in this study, such as poor compliance.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Sum of pain intensity difference in the Numeric Rating Scale (NRS) within 14 days after the first study drug treatment (SPID14) | 1 to 14 days after receiving study treatment | ①Average pain intensity is calculated daily for the past 24 hours using the NRS (0 = No pain, 10 = Worst pain imaginable). ②PID (pain intensity difference): Baseline pain intensity score (for the day prior to the day of randomization) minus pain intensity score at each given day.③SPID: the sum of the pain intensity difference generated daily from day 1 to the designated day. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of subjects who achieve effective pain control | 1 to 14 days after receiving study treatment | Effective pain control: mean NRS score within 0-3 points and episode of breakthrough pain ≤ 2 times in 24 hours |
| Time to achieve effective pain control | 1 to 14 days after receiving study treatment | — |
| Time-specific pain intensity difference（PID） | 1 to 14 days after receiving study treatment | — |
| Sum of pain intensity difference (SPID) in the NRS within 3,5 and 7 days post-treatment | from day 1 to 3, 5 and 7 after receiving study treatment, respectively | — |
| Time-specific subject self-rated pain relief based on Brief Pain Inventory Short Form (BPI-SF) Questionnaire Item 8 | 1 to 14 days after receiving study treatment | The pain relief is assessed daily for the past 24 hours based on the percentage of relief from baseline, ranging from 0 (no relief) to 100% (complete relief). |
| Sum of subject self-rated pain relief based on BPI-SF Questionnaire Item 8 within 3,5,7 and 14 days post-treatment | from day 1 to 3, 5, 7 and 14 after receiving study treatment, respectively | — |
| Proportion of subjects with pain response over 7 and 14 days after treatment | 1 to 14 days after receiving study treatment | Pain response: at least 30% and 50% decrease in pain intensity NRS score from baseline. |
| Time to pain response | 1 to 14 days after receiving study treatment | — |
| The number of breakthrough pain episodes and rescue dose of immediate-release oxycodone over 7 and 14 days after treatment; | 1 to 14 days after receiving study treatment | — |
| Time-specific oxycodone dose, including immediate-release oxycodone capsules and sustained-release oxycodone tablets (the latter is only applicable for phaseⅡb) | 1 to 14 days after receiving study treatment | — |
| Total dose of oxycodone over 3, 7, and 14 days post-treatment | 1 to 14 days after receiving study treatment | — |
| Patient's global impression of change (PGI-C) over 7 and 14 days after treatment (for phase IIb only) | 1 to 14 days after receiving study treatment | PGI-C is a participant rated instrument to measure participant's change in overall status of general condition including pain on a 7-point scale, with 1 being "very much improved" and 7 being "very much worse". |
| Frequency and severity of adverse events during treatment | 1 to 14 days after receiving study treatment | — |
Contacts
CONTACTQiling Huang
PRINCIPAL_INVESTIGATORSuxia Luo
Henan Cancer Hospital
Outcome results
None listed